Medivir (DB:MVR0) - Stock Price, News & Analysis

MVR0 Stock Overview

A pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally. More details

MVR0 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Revenue is forecast to grow 66.23% per year

Risk Analysis

Makes less than USD$1m in revenue (SEK7M)

Shareholders have been substantially diluted in the past year

Has less than 1 year of cash runway

Highly volatile share price over the past 3 months compared to the German market

+ 2 more risks

Medivir AB (publ) Competitors

Medigene

XTRA:MDG1

€22.6m

Heidelberg Pharma

XTRA:HPHA

€103.9m

co.don

XTRA:CNW

€6.5m

2invest

XTRA:2INV

€63.8m

Price History & Performance

Summary of all time highs, changes and price drops for Medivir
Historical stock prices
Current Share Price	SEK 0.22
52 Week High	SEK 0.43
52 Week Low	SEK 0.19
Beta	-0.23
11 Month Change	-2.70%
3 Month Change	-17.56%
1 Year Change	-27.13%
33 Year Change	-78.95%
5 Year Change	-89.36%
Change since IPO	-99.33%

Recent updates

Shareholder Returns

	MVR0	DE Biotechs	DE Market
7D	-1.8%	-0.7%	-0.02%
1Y	-27.1%	-17.2%	8.2%

Return vs Industry: MVR0 underperformed the German Biotechs industry which returned -17.2% over the past year.

Return vs Market: MVR0 underperformed the German Market which returned 8.2% over the past year.

Price Volatility

Is MVR0's price volatile compared to industry and market?
MVR0 volatility
MVR0 Average Weekly Movement	12.4%
Biotechs Industry Average Movement	6.4%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: MVR0's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: MVR0's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
1987	10	Jens Lindberg	www.medivir.com

Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It is also developing Remetinostat for treating MF cutaneous T-cell lymphoma and basal cell carcinoma, as well as squamous cell carcinoma.

Medivir AB (publ) Fundamentals Summary

How do Medivir's earnings and revenue compare to its market cap?
MVR0 fundamental statistics
Market cap	€26.43m
Earnings (TTM)	-€10.17m
Revenue (TTM)	€611.58k

43.2x

P/S Ratio

-2.6x

P/E Ratio

Is MVR0 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MVR0 income statement (TTM)
Revenue	SEK 7.03m
Cost of Revenue	SEK 97.07m
Gross Profit	-SEK 90.03m
Other Expenses	SEK 26.89m
Earnings	-SEK 116.92m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 18, 2025

Earnings per share (EPS)	-1.04
Gross Margin	-1,280.14%
Net Profit Margin	-1,662.48%
Debt/Equity Ratio	0%

How did MVR0 perform over the long term?

See historical performance and comparison

MVR0 Stock Overview

Rewards

Risk Analysis

Medivir AB (publ) Competitors

XTRA:MDG1

€22.6m

XTRA:HPHA

€103.9m

XTRA:CNW

€6.5m

XTRA:2INV

€63.8m

Price History & Performance

Recent News & Updates

Third quarter 2024 earnings released: kr0.30 loss per share (vs kr0.42 loss in 3Q 2023)

Medivir AB (Publ) Appoints Nomination Committee

Medivir Presents Positive, Mature Data from its Ongoing Phase 1b / 2a Study of fostroxacitabine bralpamide (fostrox) + Lenvima in Advanced Liver Cancer (hepatocellular carcinoma/HCC) at the European Society of Medical Oncology Congress

Medivir AB to Present Mature Clinical Data for Fostrox + Lenvima at ESMO Conference

Second quarter 2024 earnings released: kr0.32 loss per share (vs kr0.48 loss in 2Q 2023)

Medivir AB (publ) to Report First Half, 2025 Results on Aug 21, 2025

Recent updates

Third quarter 2024 earnings released: kr0.30 loss per share (vs kr0.42 loss in 3Q 2023)

Medivir AB (Publ) Appoints Nomination Committee

Medivir Presents Positive, Mature Data from its Ongoing Phase 1b / 2a Study of fostroxacitabine bralpamide (fostrox) + Lenvima in Advanced Liver Cancer (hepatocellular carcinoma/HCC) at the European Society of Medical Oncology Congress

Medivir AB to Present Mature Clinical Data for Fostrox + Lenvima at ESMO Conference

Second quarter 2024 earnings released: kr0.32 loss per share (vs kr0.48 loss in 2Q 2023)

Medivir AB (publ) to Report First Half, 2025 Results on Aug 21, 2025

Medivir AB to Present Updated Clinical Data for Fostrox + Lenvima in Hepatocellular Cancer At ESMO Conference in September Stockholm

New major risk - Financial position

Medivir AB Presents Positive New Data from Its Ongoing Phase Ib / IIa Study of Fostroxacitabine Bralpamide (Fostrox) + Lenvima® in Advanced Hepatocellular Carcinoma (HCC)

Medivir Selects Global CRO Partner for Upcoming Phase 2B Study in HCC with fostrox + Lenvima and Initiates Study Feasibility

Medivir Aktiebolag (publ) Approves Board Appointments

First quarter 2024 earnings released: kr0.23 loss per share (vs kr0.34 loss in 1Q 2023)

Full year 2023 earnings released: kr1.22 loss per share (vs kr1.59 loss in FY 2022)

Medivir AB (publ) to Report Q3, 2024 Results on Nov 06, 2024

Medivir AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 20.000001 million.

New major risk - Shareholder dilution

Medivir AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 20.000001 million.

Medivir Presents the First Clinical Data with Fostrox + Lenvima At the Asco GI Scientific Congress

Medivir AB Announces Further Improved Clinical Benefit with Fostrox + Lenvima as Data from the Ongoing Phase 1B/2A Study in Advanced Hepatocellular Cancer

Medivir AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 128.961315 million.

Medivir AB Announces Data from Ongoing Phase 1B/2A Study in Advanced Hepatocellular Cancers

Medivir AB Announces Updated Formulation of Fostrox Critical to Support Planned Study with Accelerated Approval Intent in Second Line HCC

Medivir AB Announces Updated Formulation of Fostrox Critical to Support Planned Study with Accelerated Approval Intent in Second Line HCC

Medivir AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 147.979713 million.

Third quarter 2023 earnings released: kr0.42 loss per share (vs kr0.27 loss in 3Q 2022)

Medivir AB (publ) to Report First Half, 2024 Results on Aug 22, 2024

Medivir AB (publ) to Report Q1, 2024 Results on Apr 30, 2024

Medivir AB (publ), Annual General Meeting, May 07, 2024

Medivir AB (Publ) Announces Resignation of Anette Lindqvist as Director

Medivir AB Announces All Patients in the Ongoing Phase 2A Study in Advanced Hepatocellular Car Car Car Carcinoma Has Now Dosed At Least Two Treatment Cycle

Medivir AB Reports Promising Interim Data, Including A First Complete Response in Phase 1B/2A Hcc Study with Fostrox in Combination with Lenvima

High number of new and inexperienced directors

Second quarter 2023 earnings released: kr0.48 loss per share (vs kr0.41 loss in 2Q 2022)

Medivir AB Announces 15th Patient with Advanced Liver Cancer Has Been Included in the Ongoing Phase 2A Study

Medivir AB Announces Formation of A Scientific Advisory Council

Medivir AB Announces Patent Application for Fostrox Approval in China

Medivir AB Completes the Dose Escalation Part (Phase 1B) of the 1B/2A Study in Hcc and Focus on the Combination of Fostrox and Lenvima

Full year 2022 earnings released: kr1.59 loss per share (vs kr1.20 loss in FY 2021)

Forecast to breakeven in 2024

Less than half of directors are independent

Medivir Completes A Successful Pre-IND Meeting with the FDA

Medivir AB (Publ) Appoints Pia Baumann as New Chief Medical Officer

Medivir AB (Publ) Appoints Nomination Committee

Medivir AB (publ) to Report Q2, 2023 Results on Aug 18, 2023

Medivir AB (publ) to Report Q1, 2023 Results on Apr 27, 2023

Medivir Aktiebolag (Publ) Announces Board Changes

Medivir AB (publ) to Report Fiscal Year 2021 Final Results on Apr 05, 2022

Medivir AB (Publ) Announces Phase II Study of Miv-711 for Osteoarthritis Shows Statistically Significant Reduction in Oa Pain

Medivir AB (publ) Announces Abstract for MIV-818 phase 1b monotherapy for ESMO Congress published

Medivir AB Announces Positive Data from the Remetinostat Phase II Study in Basal Cell Carcinoma Published in Clinical Cancer Research

Medivir Announces the Design of its Upcoming MIV-818 Combination Study

Medivir AB Announces Positive Results from Investigator-Initiated Phase II Clinical Study of Remetinostat in Patients with Squamous Cell Carcinoma

Medivir AB (publ), Annual General Meeting, May 05, 2021

Medivir AB Announces Delisting of Paid Subscription Shares

Medivir AB Enters into Licensing Agreement with Ubiquigent Limited for Preclinical Program USP7

New 90-day low: €0.79

IGM Biosciences, Inc. Enters into Exclusive Licensing Agreement with Medivir for Birinapant

New 90-day low: €0.80

Medivir AB (Publ) Renegotiates its agreement with TetraLogic Pharmaceuticals Corporation